Role of chemotherapy against micrometastatic cancer

Cancer and Metastasis Reviews

Volumn 18, Issue 1, 1999, Pages 151-172

  Harstrick, Andreas ^a   Klaassen, Ute ^a   Eberhardt, Wilfried ^a   Seeber, Siegfried ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GONADORELIN DERIVATIVE; HEMOPOIETIC GROWTH FACTOR; HEPARIN; IRINOTECAN; LEVAMISOLE; METHOTREXATE; MITOMYCIN C; MONOCLONAL ANTIBODY; PACLITAXEL; RALTITREXED; SEMUSTINE; TAMOXIFEN; TAXANE DERIVATIVE; TIRAPAZAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; COLON CANCER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; METASTASIS; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STOMACH CANCER; TREATMENT INDICATION;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0032823742     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006233008526     Document Type: Article

References (169)

1. Róy JA, Piccart MJ: Adjuvant systemic therapy for breast cancer. Curr Opin Oncol 7: 517-522, 1995
2. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: p53 in node-negative breast carcinoma: an immunhistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13: 821-830, 1995
3. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
4. Elledge R, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, Allred DC: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J Natl Cancer Inst 87: 1254-1256, 1995
5. Elledge R, Green S, Howes L, Berardo M, Alfred DC, Clark G, Ciocca D, Osborne CK, Ravdin P, O'Sullivan J, Langone G: Bcl-2, p53 and response to tamoxifen in ER-positive metastatic breast cancer. Proc Am Soc Clin Oncol 15: 159(a), 1996
6. Makris A, Powles TJ, Dowsett M, Allred C: p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345: 1181-1182, 1995
7. Mathieu MC, Koscielny S, Le Bihan ML, Spielmann M, Arriagada R: p53 Protein overexpression and chemosensitivity in breast cancer. Lancet 345: 1182, 1995
8. Obermair A, Kurz C, Czerwenka K, Thoma M, Keider A, Wagner T, Gitsch G, Sevelda P: Microvessel density and vessel invasion in lymph-node negative breast cancer: Effect on recurrence-free survival. Int J Cancer 62: 126-131, 1995
9. Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N, Gasparine G: Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma: results of a multiparametric study. Breast Cancer Res Treat 36: 205-217, 1995
10. Axelsson K, Ljung BME, Moore DH II, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87: 997-1008, 1995
11. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, Bianco AR, De Placido S: The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 76: 1172-1178, 1995
12. Fockens JA, Buessecker F, Peters HA, Krainick U, van Putten WLJ, Look MP, Klijn JGM, Kramer MD: Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427, 1995
13. Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, Friede U, Barbazza R, Visona A, Dante S: Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31A(5): 671-677, 1995
14. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen R, Norton L: Immunohistochemical detection of HER/neu in patients with axillary lymphatic node negative breast carcinoma. Cancer 75: 1320-1326, 1995
15. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995
16. Soubeyran I, Wafflart J, Bronichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinoma: a study on 942 cases. Breast Cancer Res Treat 34: 119-128, 1995
17. 2 extracellular domain in predicting response to chemotherapy in breast cancer patients. Proc Am Soc Clin Oncol 108(15): 96a, 1996
18. Goldhirsch A, Senn H-J, Glick JH, Gelber RD: International consensus panel on the treatment of primary breast cancer V. Update 1998 in Results in Cancer Research: Adjuvant therapy of primary breast cancer. Senn HJ, Gelber RD, Goldhirsch A, Thürlimann B (eds) Springer Verlag 1998, pp 481-492
19. Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RVP: Predictors of recurrence for patients with small (one antimeter or less) localized breast cancer (Tlab N0 M0). Cancer 76: 2266-2274, 1995
20. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673-1682, 1997
21. Albein K, Green S, Osborne K, Cobau C, Levine E, Ingle J for SWOG, ECOG, CALGB, NCCTG, and NCI-Canada: Tamoxifen (T) versus cyclophosphamide, Adriamycin® and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100). (Abstract 450) Proc ASCO 16: 128a, 1997
22. Wils J, Bliss JM, Coombes RC, Woods E, Coombes G, Blijham GH for the International Collaborative Cancer Group (ICCG): A multicentre randomized trial of tamoxifen vs. tamoxifen plus epirubicin in postmenopausal women with node-positive breast cancer. (Abstract 101) Proc ASCO 15: 109, 1996
23. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15: 1385-1394, 1997
24. Gelber RD, Cole BH, Goldhirsch A, Rose C, Fisher B, Osborne CK: Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: metaanalysis of quality-adjusted survival. Lancet 347: 1066-1071, 1996
25. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542-547, 1995
26. Levine MN, Bramwell VH, Pritchard KI, Norris GD, Shepherd LE, Abu-Zahra H for the National Cancer Institute of Canada Clinical Trials Group: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651-2658, 1998
27. Fisher B, Aignam J, Wolmark N: Tamoxifen and chemotherapy for lymph node negative, estrogen-receptor positive breast cancer. J Natl Cancer Inst 89: 1673-1682, 1997
28. Bonadonna G, Valagussa P, Brambilla C, Ferrair L, Moliterni A, Terenziani M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998
29. Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16: 107-114, 1998
30. Fisher B, Brown A, Mamounas E, Wieand S, Fisher E, Robidoux A: Effect or preoperative therapy for primary breast cancer (BC) on local-regional disease, disease-free survival (DFS) and survival (S): results from NSABP B-18. (Abstract 449) Proc ASCO 16: 127A 1997
31. Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT: Randomized phase II trial of infusional fluorouracil, epirubicin and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 16: 1350-1357, 1998
32. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429, 1995
33. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S: Improved disease-free and overall survival form the addition of sequential paclitaxel but not from the escalation with node-positive primary breast cancer. (Abstract 390A) Proc Am Soc Clin Oncol 17: 101, 1998
34. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288, 1984
35. Antman KH, Rowlings PA, Vaugham WP, Pelz CJ, Fay JW, Fields KK: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870-1879, 1997
36. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with metastatic breast cancer. J Clin Oncol 15: 3171-3177, 1997
37. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gomez H, Guerra JA: Patient selection in high-dose chemotherapy trials: relevance to high-risk breast cancer. J Clin Oncol 15: 3178-3184, 1997
38. Crump M, Goss PE, Prince M, Girouard C: Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 14: 66-69, 1996
39. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Konig CCE: A ranxomized trial of high-dose chemotherapy and hematopoetic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. (Abstract 470) Proc Am Soc Clin Oncol 17: 123, 1998
40. Hortobagyi GN, Buzdar AU, Champlin R, Gajewski J, Holmes FA, Booser D: Lack of efficaca of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer (HRPBC): a randomized trial. (Abstract 471) Proc Am Soc Clin Oncol 17: 123, 1998
41. Zujewski J, Nelson A, Abrams I: Much ado about not enough data; high-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 90: 200-209, 1998
42. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. (Abstract 376) Proc Am Soc Clin Oncol 17: 97, 1998
43. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial. (Abstract 377) Proc Am Soc Clin Oncol 17: 98, 1998
44. Bianco AR, deLaurentiis M, Carlomagno C, Lauria R, Petrella G: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-b2 expression and tamoxifen efficacy. (Abstract 373) Proc Am Soc Clin Oncol 17: 97, 1998
45. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, Pritchard K: Initial report of the SWOG biological correlative study of c-erb-b2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen alone. (Abstract 374) Proc Am Soc Clin Oncol 17: 97, 1998
46. Gudjonsson B: Cancer of the pancreas: 50 years of surgery. Cancer 60: 2284-2303, 1987
47. Trede M, Chri B, Seeger HD: Survival after pancreaticoduodenectomy. Ann Surg 21(4): 447-458, 1990
48. Yeo CJ, Cameron JL, Lillemoe KD, Sitzman JV, Hruban RH, Goodman SN, Dooley WC, Coleman JA, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. Two hundred and one patients. Ann Surg 221(6): 721-733, 1995
49. Kaser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 123: 899-903, 1985
50. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006-2010, 1987
51. Klinkenbijl JHG, Sahmoud T, van Pel R, Couvreur ML, Veenhof CHN, Arnaud JP, Hennipman A, Wils J, Jeckel J: Radiotherapy and 5-Fu after curative resection for cancer of the pancreas and peri-ampullary region: A phase III trial of the EORTC and GITCCG (Abstract 1239) Eur J Cancer 33(8), 1997
52. Yeo CJ, Abrams RA, Crochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak M, Dooley WC, Coleman JA, Souter PK, Pitt HA, Lillemoe KD, Cameron JL: Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival: A prospective, single-institution experience. Ann Surg 225(5): 621-636, 1997
53. Spitz FR, Abbruzzese JL, Lee JE, Pisters PWT, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Richt TA, Evans DB: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15(3): 928-937, 1997
54. Foo ML, Gunderson LL, Nagorney DM, McLLrath DC, van Heerden JA, Robinow JS, Kvols LK, Garton GR, Martenson JA, Cha SS: Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ±5 fluorouracil. Int J Radiation Oncology Biol Phys 26: 483-489, 1993
55. Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Door FA, Stephens CD, van Hoff DD: Improvements in survival and clinical benefit with gerncitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15(6): 2403-2413, 1997
56. Regine WF, Abrams RA: Adjuvant therapy for pancreatic cancer: Back to the future. Int J Radiat Oncology Biol Phys 1(42): 59-63, 1998
57. Akoh JA, Macintyre IMC: Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Cancer 79: 293-299, 1970
58. Roder JD, Böttcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ and the German Gastric Carcinoma Study 1992: Prognostic Factors in Gastric Carcinoma. Cancer 72: 2089-2097, 1993
59. Nakamura K, Ucyama T, Yao T, Xuan ZX, Ambe K, Adachi Y: Pathology and prognosis of gastric carcinoma: findings in 10,000 patients who underwent primary gastrectomy. Cancer 70: 1030-1037, 1992
60. Fink U, Stein HJ, Siewert JR: Multimodale Therapie bei Tumoren des oberen Gastrointestinaltraktes. Chirurg 69: 349-359, 1998
61. Gunderson L, Sosin H: Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symptomatic look) clinico-pathologic correlation and implication for adjuvant therapy. Int J Radiation Oncol Biol Phys 8: 1-11, 1982
62. McNeer G, Vanderberg H, Donn F: A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann Surg 134: 1-7, 1951
63. Wisbeck WM, Becher EM, Russel AH: Adenocarcinoma of the stomach: Autopsy observation with therapeutic implications for the radiation oncologist. Radiother Oncol 7: 13-18, 1986
64. Wils JA, Klein HO, Wagener DJT: Sequential high dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: A trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 827-831, 1991
65. Webb A, Cunningham D, Scarffe JH: A randomized trial comparing epirubicin, cisplatin and protracted venous infusion 5-fluorouracil with 5-fluorouracil, adriamycin and methotrexate in advanced oesophago-gastric cancer. (Abstract 1462) Proc Am Soc Clin Oncol 15: 465, 1996
66. Wilke H, Korn M, Köhne C: Phase II results of weekly infusional high dose FU plus folinic acid and biweekly cisplatin for advanced gastric cancer. (Abstract 2130) Ann Oncol 7 (Suppl 5): 46, 1996
67. Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49: 1116-1122, 1982
68. Engstrom PF, Lavin PT, Douglass HO Jr: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group Study (EST 3275): Cancer 55: 1868-1873, 1985
69. Higgins GA, Amadeo JH, Smith DE: Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology Group report. Cancer 52: 1105-1112, 1983
70. Coombes RC, Schein PS, Chilvers CE: A randomized trial of comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 8: 1362-1369, 1990
71. Hallissey MT, Dunn JA, Ward LC: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up. Lancet 343: 1309-1312, 1994
72. Macdonald JS, Gagliano R, Fleming T: A phase III trial of FAM (5-Fluorouracil, Adriamycin, mitomycin C) chemotherapy vs control as adjuvant treatment for resected gastric cancer: A Southwest Oncology Group Trial. (Abstract) Proc Am Soc Clin Oncol 11: 168, 1992
73. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Dos Santos JG, Labianca R, Rougier P, Gignoux M: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in Resectable Gastric Cancer. J Clin Oncol 13: 2757-2763, 1995
74. Hermans J, Bonenkamp JJ, Boon MC, Bunl AMG, Ohyama S, Sasako M, Van der Velde CJH: Adjuvant Therapy After Curative Resection for Gastric Cancer: Meta-Analysis of Randomized Trials. J Clin Oncol 11: 1441-1447, 1993
75. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer: revisiting a meta-analysis of randomized trial. (Abstract 1009) Proc Am Soc Clin Oncol 17: 263, 1998
76. Archer S, Gray B: Intraperitoneal 5-Fluorouracil infusion for treatment of both peritoneal and liver micrometastasis. Surgery 108: 502-507, 1990
77. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Sem Oncol 16: 83-97, 1989
78. Hagiwara A, Takahashi T, Kojima O: Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 330: 629-631, 1992
79. Rosen HR, Jatzko G, Repse S, Potre S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czejka M: Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 16: 2733-2738, 1998
80. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12: 970-974, 1994
81. Ajani JA, Mayer RJ, Ota DM: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 85: 1839-1844, 1993
82. Leichman L, Silberman H, Leichman CG: Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California pilot program. J Clin Oncol 10: 1933-1942, 1992
83. Fink U, Schuhmacher C, Stein HJ, Busch R: Preoperative chemotherapy for stage III IV gastric carcinoma; Feasibility, response, and outcome after surgical resection. Br J Surg 82: 1248, 1995
84. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306: 752-755, 1994
85. Buyse M, Zeleniuch-Jacquotte A, Chalmers, TC: Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259: 3571-3578, 1988
86. Laurie J, Moertel CG, Fleming T: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and combination of levamisole and fluorouracil. J Clin Oncol 7: 1447-1456, 1989
87. Buroker TR, Moertel CG, Fleming TR: A controlled evaluation of rectal approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 3: 1624-1631, 1985
88. Moertel CG, Fleming TR, MacDonald JS: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990
89. Moertel CG, Fleming T, MacDonald JS: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma. A final report. Ann Intern Med 122: 321-326, 1995
90. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992
91. IMPACT Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 106: 939-944, 1995
92. Haller DG, Catalano PJ, MacDonald JS: Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: Five-year final report of INT-0089. (Abstract 982) Proc Am Soc Clin Oncol 17, 1998
93. O'Connel MJ, Laurie JA, Shephard C: A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada trials group. (Abstract): Proc Am Soc Clin Oncol 15: 209, 1996
94. Mamounas EP, Rockette H, Jones J: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B and C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). (Abstract) Proc Am Soc Clin Oncol 15: 205, 1996
95. Harrison LE, Guillem JG, Paty Ph, Cohen AM: Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 185: 55-59, 1997
96. Shibata D, Reale MA, Lavin Ph: The DCC protein and prognosis in colorectal cancer. N Engl J Med 335(23): 1727-1732, 1996
97. Jen J, Kim J, Piantadosi St: Allelic Joss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331(4): 213-221, 1994
98. Futamura M, Takagi Y, Koumura H: Spread of colorectal cancer micrometastases in regional lymph nodes by reverse transcriptase-polymerase chain reactions for carcinoembryonic antigen and cytokeratin 20. J Surg Oncol 68(1): 34-40, 1998
99. Liefers G-J, Cleton-Jansen A-M, van der Velde CJH: Micrometastases and survival in stage II colorectal cancer. N Engl Med 339: 223-228, 1998
100. Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J. Surg 72: 359-363, 1985
101. Beart RW Jr, Moertel CG, Wieand HS, Leigh JE, Windschitl HE, van Heerden JA: Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and North Central Cancer Treatment Group. Arch Surg 125: 897-901, 1990
102. Fielding LP, Hittinger R, Grace RH, Fry JS: Randomised controlled trial of adjuvant chemotherapy by portal-vein infusion after curative resection for colorectal adenocarcinoma. Lancet 340: 502-506, 1992
103. Swiss Group for Clinical Cancer Research (SAKK): Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345: 349-353, 1995
104. Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL: Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase control. Results of a prospective randomized trial (Colorectal Adenocarcinoma Trial I). Cancer 65: 425-432, 1990
105. Wolmark N, Rockette H, Wickerham DL, Fisher B, Redmond C, Fisher ER: Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 8: 1466-1475, 1990
106. Liver Infusion Meta-Analysis Group: Portal Vein Chemotherapy for Colorectal Cancer: a Meta-analysis of 4000 Patients in 10 Studies. J Natl Cancer Inst 89: 497-505, 1997
107. Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, de Wacle B, Nakajima T, Rauschecker H, Labianca R, Pector JC, Marsoni S, Apolone G, Lasser P, Couvreur ML, Wils J: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 351: 1677-1681, 1998
108. Ginsberg RJ, Kris MG, Armstrong JG: Cancer of the Lung, Section 1: Non-small cell lung cancer. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology (edn 4). Philadelphia, PA, Lipincott, 1993, pp 673-723
109. Ihde DC, Pass HI, Glatstein EJ: Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology (edn 5). Philadelphia, PA, Lippincott, 1997, pp 911-949
110. Parker SL, Tong T, Bolden SI: Cancer statistics, 1997, Cancer 47: 5-27, 1997
111. Souse WT, Turrisi AT: Principles and application of preoperative and standard radiotherapy for regionally advanced non-small cell lung cancer. In: Pass HJ, Mitchell J, Johnson DH, Turrisi AT (eds) Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott Raven Publishers, 1996, pp 697-710
112. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1723, 1997
113. Perez CA, Pajak TF, Rubin P: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59: 1874-1881, 1987
114. Shepherd FA: Induction chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 55: 1585-1592, 1993 F
115. Feld R, Rubinstein L, Thomas P: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage 1 non-small cell lung cancer. J Natl Cancer Inst 85: 299-306, 1993
116. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. BMJ Oct 7; 311(7010): 899-909, 1995
117. Le Chevalier T: Adjuvant chemotherapy in non-small cell lung cancer. Semin Oncol 25: 62-65, 1998
118. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65(1): 25-32, 1980
119. Volm M, Koomagi R, Mattern J, Stammler G: Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 75(12): 1774-1778, 1997
120. Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M: Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16(19): 2469-2477, 1998
121. Rosell R, Molina F, Moreno I, Martinez E, Pifarre A, Font A, Li S, Skacel Z, Gomez-Codina J Camps C: Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 12: 59-70, 1995
122. Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G: Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15: 2456-2466, 1997
123. Sanchez-Cespedes M, Monzo M, Rosell R, Pifarre A, Calvo R, Lopez-Cabrerizo MP, Astudillo J: Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9:11311-6, 1998
124. Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O, Thettor O, Riethmuller G: Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 53: 1027-31, 1993
125. Izbicki JR, Passlick B, Hosch SB, Kubuschock B, Schneider C: Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance or nodal micrometastasis. J Thorac Cardiovasc Surg 112: 623-630, 1996
126. Bunn PA Jr, Kelly M: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100, 1998
127. von Pawel J, von Roemeling R, for the Intl CATAPULT-I Study Group. Survival benefit from tirazonetm (Tirapazamine) and cisplatin in advanced non-small cell lung cancer patients: Final results from the international phase III Catapult I trial. (Abstract 1749) Proc Am Soc Clin Oncol 17, 1998
128. Pritchard RS, Anthony SP K: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125: 723-729, 1996
129. Dillman RO, Seagren SL, Propert K: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Mod 323: 940-945, 1990
130. Dillman RO, Herndon J, Seagren SL, Eaton WI, Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215, 1996
131. Le Chevalier T, Arriagada R, Tarayre M, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 84: 58, 1992
132. Arriagada T, Le Chevalier C, Rekacewicz E, Quoix H, De Cremoux JY, Douillard M, Tarayre: Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): late analysis of a French randomized trial. (Abstract 1601) Proc Am Soc Clin Oncol 16, 1997
133. Choi, N: Management of stage III non-small-cell lung cancer: Progress in preoperative chemoradiotherapy. Am Soc Clin Oncol, Educational Book, pp 276-289, 1998
134. Shaw EG, McGinnis WL, Jett, JR: Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomittant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small cell carcinoma of the lung. J Natl Cancer Inst 85: 321-323, 1993
135. Sause WT, Scott C, Taylor S: RTOG 88-08 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable non-small-cell lung cancer with minimum three year follow-up. Int J Radiat Oncol Biol Phys 32: 195, 1995b
136. Saunders EG, Mc Ginnis WL, Jett JR: Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell lung cancer. Lung Cancer 9: 221-224, 1993
137. Tishler RB, Schiff PB, Geard CR: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22: 613-617, 1992
138. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4: 1931-1936, 1998
139. Rosell R, Gomez-Codina J, Camps C: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Mod 330: 153-158, 1994
140. Roth JA, Fossella FV, Komaki R: A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86: 673-680, 1994
141. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21: 1-6, 1998
142. Johnson DH, Turrisi AT, Pass HJ: Combined modality treatment for locally advanced non-small cell lung cancer. In Pass HJ, Mitchell J, Johnson DH, Turrisi AT (eds) Lung Cancer: Principles and Practice, Philadelphia, PA, Lippincott-Raven, 1996, pp 863-873
143. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Ontology. J Clin Oncol 15: 2996-3018, 1997
144. Rusch VW, Albain KS, Crowley JJ: Neoadjuvant therapy: A novel and effective treatment for stage IIIb non-small cell lung cancer. Ann Thorac Surg 58: 290-295, 1994
145. Albain KS, Rusch VW, Crowley JJ: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Ontology Group phase II study 8805. J Clin Oncol 13: 1890-1892, 1995
146. Eberhardt W, Wilke H, Stamatis G: Preoperative chemotherapy followed by concurrent chemoradiation therapy based upon hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase II trial. J Clin Oncol 16: 622-634, 1998
147. Choi NC, Carey RW, Myojnin M: Preoperative chemoradiotherapy using concurrent boost radiation and resection for good responders in stage IIIB (T4 or N3) non-small cell lung cancer: A feasibility study. (Abstract 291) Lung Cancer 18: 76, 1997
148. Grunenwald D, Le Chevalier T, Arriagada R: Results of surgical resection in stage IIIB non-small cell lung cancer (NSCLC) after concomittant induction chemoradiotherapy. (Abstract 280) Lung Cancer 18: 73, 1997
149. Arriagada R, Le Chevalier T, Borie F: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87: 183-190, 1995
150. Quoix E, Milleron B, Moro D, Braun D, Breton JL, Lebeau B, Chastang C, Janicot H, Gouva S, Lemarie E, Paillot N, Coudert B, Lebas F, Coetmeur D, Thiberville L, Brechot JM, David M, Depierre A: An ongoing multicenter trial comparing perioperative chemotherapy (CT) plus surgery, versus surgery (S) alone for resectable non-small cell lung cancer (NSCLC) (Meeting abstract). Anti-Cancer Treatment, Sixth International Congress, p 149. Paris, France, February 6-9, 1996
151. Pisters KMW, Ginsberg RJ: Phase II trial of induction paclitaxel & carboplatin in early stage (T2N0, T1-2NI, & selected T3N0-1) non-small cell lung cancer. (Abstract 1738) Proc Am Soc Clin Oncol 17: 1998
152. Frei E 3rd: Non-small cell lung cancer: novel treatment strategies, Chest 112: 266S-268S, 1997
153. Elias AD: Small cell lung cancer: State-of-the-art therapy in 1996, Chest 112: 251-258, 1997
154. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10: 890-895, 1992
155. Pignon JP, Arriagada R, Ihde DC: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Mod 327: 1618-1624, 1992
156. Turrisi AT, Glover DJ, Mason B: Long term results of platinum etoposide + twice daily thoracic radiotherapy for limited small-cell lung cancer: results on 32 patients with 48 months minimum F/U. (Abstract 975) Proc Am Soc Clin Oncol 11: 292, 1992
157. McCracken JD, Janaki LM, Crowley JJ: Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol 8: 892-898, 1990
158. Johnson DH, Kim K, Sause W, et al.: Cisplatin and etoposide plus thoracic radiotherapy administered once or twice daily in limited disease small cell lung cancer: Final report or Intergroup Trial 0096. (Abstract 1113) Proc Am Soc Clin Oncol 15: 374, 1996
159. Murray N, Payne DG, Coldman AJ: Multimodality therapy for limited stage small cell lung cancer: combining chemotherapy and thoracic irradiation. In: Pass HJ, Mitchell J, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott Raven Publishers, 1996, pp 875-898
160. Takada M, Fukoka M, Furuse K: Phase III Study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: Preliminary results or the Japan Clinical Ontology Group. (Abstract 1103) Proc Am Soc Clin Oncol 15: 372, 1996
161. Elias A: Dose-intensive therapy in lung cancer. Cancer Chemother Pharmacol 40: S64-S69, 1997
162. Le Cesne A, Le Chevalier T, Arriagada R: Dealing with initial chemotherapy doses: a new basis for treatment optimisation in limited small-cell lung cancer. Ann Oncol 6: 53-56, 1995
163. Thatcher N, Sambrock RJ, Stephens RJ, Qian W, Hoppwood, P, Girling DJ: Dose intensification with G-CSF improves survival in small-cell lung cancer: Results of a randomized trial. (Abstract 1754) Proc Am Soc Clin Oncol 17, 1998
164. Felscher S, Bragger W, Engelhardt R, et al.: Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited - and extensive disease small-cell lung cancer. Ann Oncol 8: 49-56, 1997
165. Shepherd F: Surgical management of small-cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia, Lippincott-Raven, 1996, pp 889-913
166. Eberhardt W, Stamatis G, Stuschke M, Wilke H, Stahl M, Müller MR, Budach V, Konietzko N, Sack H, Seeber S: Aggressive trimodality treatment including chemoradiation induction and surgery in LD-small-cell lung cancer - Long-term results. (Abstract 1735) Proc Am Soc Clin Oncol 17, 1998
167. Lad T, Piantadosi S, Thomas P: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small-cell lung cancer to combination chemotherapy. Chest 106: 320-323, 1994
168. Shepherd FA: Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. Lung Cancer 17: 121-136, 1997
169. Grant SC, Kris MG, Miller V, Yao TJ, Houghton AN, Chapman PBT: Long survival in 15 patterns (pts) with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: an update. (Abstract 1630) Proc Am Soc Clin Oncol 16, 1997